Mersana Therapeutics (MRSN) News Today $0.45 +0.00 (+0.74%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$0.45 0.00 (-0.47%) As of 03/25/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Brokerages Set Mersana Therapeutics, Inc. (NASDAQ:MRSN) Target Price at $4.25March 16, 2025 | americanbankingnews.comMersana at Leerink Global Healthcare Conference: Strategic ADC InsightsMarch 14, 2025 | investing.comMersana Therapeutics, Inc. (NASDAQ:MRSN) Given Consensus Recommendation of "Moderate Buy" by BrokeragesShares of Mersana Therapeutics, Inc. (NASDAQ:MRSN - Get Free Report) have been given an average rating of "Moderate Buy" by the six analysts that are presently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating, three have issued a buyMarch 13, 2025 | marketbeat.comQ1 EPS Estimates for Mersana Therapeutics Cut by WedbushMersana Therapeutics, Inc. (NASDAQ:MRSN - Free Report) - Research analysts at Wedbush reduced their Q1 2025 EPS estimates for shares of Mersana Therapeutics in a report issued on Monday, March 3rd. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of ($0.25) per shMarch 7, 2025 | marketbeat.comWhat is William Blair's Estimate for MRSN Q1 Earnings?Mersana Therapeutics, Inc. (NASDAQ:MRSN - Free Report) - Investment analysts at William Blair issued their Q1 2025 earnings per share estimates for shares of Mersana Therapeutics in a research report issued to clients and investors on Monday, March 3rd. William Blair analyst A. Hsieh expects thatMarch 7, 2025 | marketbeat.comEarnings Update: Mersana Therapeutics, Inc. (NASDAQ:MRSN) Just Reported And Analysts Are Boosting Their EstimatesMarch 6, 2025 | finance.yahoo.comWhat is Leerink Partnrs' Forecast for MRSN FY2025 Earnings?Mersana Therapeutics, Inc. (NASDAQ:MRSN - Free Report) - Stock analysts at Leerink Partnrs dropped their FY2025 earnings estimates for shares of Mersana Therapeutics in a research note issued on Monday, March 3rd. Leerink Partnrs analyst J. Chang now expects that the company will post earnings ofMarch 6, 2025 | marketbeat.comIndustry Analysts Just Made A Captivating Upgrade To Their Mersana Therapeutics, Inc. (NASDAQ:MRSN) Revenue ForecastsMarch 6, 2025 | finance.yahoo.comMersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2024 Earnings Call TranscriptMarch 4, 2025 | insidermonkey.comAnalysts Set Expectations for MRSN Q1 EarningsMersana Therapeutics, Inc. (NASDAQ:MRSN - Free Report) - Analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of Mersana Therapeutics in a report released on Monday, March 3rd. Leerink Partnrs analyst J. Chang anticipates that the company will earn ($0.17) perMarch 4, 2025 | marketbeat.comWedbush Reaffirms Outperform Rating for Mersana Therapeutics (NASDAQ:MRSN)Wedbush reiterated an "outperform" rating and issued a $4.00 price target on shares of Mersana Therapeutics in a research note on Monday.March 3, 2025 | marketbeat.comMersana Therapeutics, Inc.: Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2024 Financial ResultsMarch 3, 2025 | finanznachrichten.deMersana Therapeutics reports Q4 EPS (11c), consensus (17c)March 3, 2025 | markets.businessinsider.comMersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2024 Financial ResultsMarch 3, 2025 | finance.yahoo.comMersana Therapeutics (NASDAQ:MRSN) Posts Earnings Results, Beats Expectations By $0.05 EPSMersana Therapeutics (NASDAQ:MRSN - Get Free Report) posted its quarterly earnings results on Monday. The company reported ($0.11) EPS for the quarter, topping analysts' consensus estimates of ($0.16) by $0.05. Mersana Therapeutics had a negative net margin of 214.20% and a negative return on equity of 401.37%.March 3, 2025 | marketbeat.comMersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2024 Financial ResultsMarch 3, 2025 | globenewswire.comMersana Therapeutics faces Nasdaq delisting over share priceMarch 2, 2025 | uk.investing.comMersana Therapeutics Q4 2024 Earnings PreviewFebruary 28, 2025 | msn.comMersana Therapeutics to Present at Upcoming Investor ConferencesFebruary 25, 2025 | globenewswire.comMersana Therapeutics to Host Fourth Quarter and Year End 2024 Conference Call on March 3, 2025February 24, 2025 | globenewswire.comMersana Therapeutics (MRSN) Expected to Announce Earnings on WednesdayMersana Therapeutics (NASDAQ:MRSN) will be releasing earnings before the market opens on Wednesday, February 26.February 19, 2025 | marketbeat.comMersana Therapeutics, Inc. (NASDAQ:MRSN) Given Average Rating of "Moderate Buy" by AnalystsShares of Mersana Therapeutics, Inc. (NASDAQ:MRSN - Get Free Report) have been assigned an average rating of "Moderate Buy" from the nine brokerages that are covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation, six have assigned a buyFebruary 16, 2025 | marketbeat.comWhat is William Blair's Estimate for MRSN FY2024 Earnings?Mersana Therapeutics, Inc. (NASDAQ:MRSN - Free Report) - Equities researchers at William Blair issued their FY2024 earnings per share (EPS) estimates for Mersana Therapeutics in a report released on Wednesday, February 5th. William Blair analyst A. Hsieh forecasts that the company will post earniFebruary 10, 2025 | marketbeat.comMersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)February 7, 2025 | globenewswire.comWilliam Blair starts Mersana stock with Outperform ratingFebruary 6, 2025 | msn.comWilliam Blair Initiates Coverage of Mersana Therapeutics (MRSN) with Outperform RecommendationFebruary 6, 2025 | msn.comMersana Therapeutics (NASDAQ:MRSN) Coverage Initiated at William BlairWilliam Blair assumed coverage on Mersana Therapeutics in a report on Thursday. They set an "outperform" rating for the company.February 6, 2025 | marketbeat.comMersana Therapeutics initiated with an Outperform at William BlairFebruary 6, 2025 | markets.businessinsider.comMersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech ConferenceJanuary 30, 2025 | globenewswire.comBrokerages Set Mersana Therapeutics, Inc. (NASDAQ:MRSN) Price Target at $5.57Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN - Get Free Report) have been given a consensus rating of "Moderate Buy" by the eight analysts that are presently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation, five have issueJanuary 25, 2025 | marketbeat.comMRSN stock touches 52-week low at $0.56 amid market challengesJanuary 21, 2025 | msn.comMersana Therapeutics CEO sells $2,618 in stockJanuary 18, 2025 | msn.comMersana Therapeutics chief development officer sells shares worth $3,444January 18, 2025 | msn.comMersana Therapeutics' chief accounting officer sells shares worth $2,061January 17, 2025 | msn.comMersana Therapeutics officer Timothy Lowinger sells $4,667 in stockJanuary 17, 2025 | msn.comMersana Therapeutics' chief legal officer sells $599 in stockJanuary 16, 2025 | msn.comMersana therapeutics VP Mandelia sells $1,128 in stockJanuary 16, 2025 | msn.comBTIG Sticks to Its Buy Rating for Mersana Therapeutics (MRSN)January 12, 2025 | markets.businessinsider.comBuy Rating for Mersana Therapeutics: Promising Efficacy and Safety of Emi-Le ADC Amid Stock Price VolatilityJanuary 11, 2025 | markets.businessinsider.comMersana Therapeutics selloff on data overdone, says BTIGJanuary 11, 2025 | markets.businessinsider.comMersana Therapeutics (NASDAQ:MRSN) Stock, Insider Trading ActivityJanuary 11, 2025 | benzinga.comMersana Therapeutics (NASDAQ:MRSN) Stock Quotes, Forecast and News SummaryJanuary 11, 2025 | benzinga.comMersana Therapeutics, Inc.: Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)January 10, 2025 | finanznachrichten.deMersana Therapeutics: Promising Clinical Data and Strong Financial Position Justify Buy RatingJanuary 10, 2025 | markets.businessinsider.comMersana falls after early-stage trial data for lead cancer therapyJanuary 10, 2025 | msn.comWhy Is Cancer-Focused Mersana Therapeutics Stock Trading Lower On Friday?January 10, 2025 | finance.yahoo.comMersana Shares Rise on Advances With Breast-Cancer TreatmentJanuary 10, 2025 | marketwatch.comMersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)January 10, 2025 | markets.businessinsider.comMersana Therapeutics: FDA Grants Additional Fast Track Designation To XMT-1660January 10, 2025 | markets.businessinsider.comMersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)January 10, 2025 | globenewswire.com Remove Ads Get Mersana Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MRSN and its competitors with MarketBeat's FREE daily newsletter. Email Address MRSN Media Mentions By Week MRSN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MRSN News Sentiment▼0.000.77▲Average Medical News Sentiment MRSN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MRSN Articles This Week▼12▲MRSN Articles Average Week Remove Ads Get Mersana Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MRSN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies INMB News Today TVGN News Today VYGR News Today ELDN News Today INBX News Today ACIU News Today DMAC News Today BTMD News Today SOPH News Today NGNE News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MRSN) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mersana Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mersana Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
